Abstract Objective To compare the survival between three-dimensional radiotherapy (3DRT) alone and concurrent chemoradiotherapy (C+3DRT) for non-surgical esophageal carcinoma. Methods Four hundred and eighty patients with esophageal squamous cell carcinoma who were treated with definitive 3DRT or C+3DRT in our institution from 2002 to 2012 were collected and 296 out of them were equally divided into 3DRT group and C+3DRT group. Survival comparison between the two groups was made by propensity score matching method. Patients were mainly given paclitaxel and platinum weekly in C+3DRT. Results The numbers of samples at 3 and 5 years were 58 and 48 in the 3DRT group, and 58 and 52 in the C+3DRT group. The 3-and 5-year overall survival (OS) rates were 32.6% and 22.1% in the 3DRT group, and 35.1% and 26.5% in the C+3DRT group (P=0.463).The 3-and 5-year progression-free survival (PFS) rates were 27.8% and 19.8% in the 3DRT group, and 30.7% and 25.8% in the C+3DRT group (P=0.637). In the 3DRT and C+3DRT groups, patients treated with 60.0－70.0 Gy had similar OS rates (25.6% vs. 25.3%, P=0.833), PFS rates (22.7% vs. 25.2%, P=0.999), and incidence rates of hematogenous metastasis (23.4% vs. 24.1%, P=0.899) at 5 years. Patients treated with 50.0－59.9 Gy had significantly higher 5-year OS and PFS rates in the C+3DRT group than in the 3DRT group (32.3% vs. 12.0%,P=0.030;24.1% vs. 10.6%,P=0.087). In the 3DRT group, patients treated with 60.0－70.0 Gy had significantly higher 5-year OS and PFS rates than those treated with 50.0－59.9 Gy (P=0.024,P=0.041). In the C+3DRT group, patients treated with 60.0－70.0 Gy and 50.0－59.9 Gy had similar 5-year OS and PFS rates (P=0.791,P=0.984). The incidence rates of adverse reactions, such as esophagitis and leukopenia, in the C+3DRT group were significantly higher than those in the 3DRT group (P=0.000,P=0.005). However, those adverse reactions could be tolerated by patients. Conclusions For patients with non-surgical esophageal carcinoma, a low dose in definitive C+3DRT is recommended. 60－70 Gy in 3DRT alone can also achieve a promising survival in patients who cannot receive C+3DRT, which still needs to be confirmed by randomized studies.
Tan Lijun,Xiao Zefen,Zhang Hongxing et al. Survival comparison of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(2): 106-110.
Tan Lijun,Xiao Zefen,Zhang Hongxing et al. Survival comparison of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(2): 106-110.
[1]Globocan 2012. Estimated cancer incidence mortality and prevalience wordwide in 2012[DB/OL][2014-10-10].http://globocan.iarc.fr/Pages/online.aspx. [2]肖泽芬.食管癌[A]//殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2008:546-573. [3]殷蔚伯,张力军,杨宗贻,等.放射治疗食管癌3798例临床分析[J].中华肿瘤杂志,1980,2(3):216-220. [4]上海市肿瘤医院放射治疗科.1034例食管癌放射治疗临床分析[J].肿瘤防治研究,1978,6(4):46-51. [5]Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85－01). Radiation Therapy Oncology Group[J]. JAMA,1999,281(17):1623-1627. [6]Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123(Radiation Therapy Oncology Group 94－05) phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy[J]. J Clin Oncol,2002,20(5):1167-1174. [7]Liu MN, Shi XH, Guo XM, et al. Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma:a final report on a prospective trial[J/OL]. Radiat Oncol,2012,7:142[2014-10-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494533/.DOI:10.1186/1748－717X-7-142. [8]王新强,程秀祯,王世伟,等.放疗联合PF方案同步治疗中晚期食管癌[J].中华放射肿瘤学杂志,2005,14(3):215. [9]Sobin LH, Wittekind CH. TNM classification of malignant tumours[M]. New York:Wildy-Liss,2002. [10]Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus[J]. N Engl J Med,1992,326(24):1593-1598. [11]al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer:an intergroup study[J]. J Clin Oncol,1997,15(1):277-284. [12]Smith TJ, Ryan LM, Douglass HO Jr, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus:a study of the Eastern Cooperative Oncology Group[J]. Int J Radiat Oncol Biol Phys,1998,42(2):269-276. [13]刘俊,吕长兴,王家明,等.同步放化疗治疗不能手术的食管癌临床结果[J].中华放射肿瘤学杂志,2006,15(3):185-187. [14]Smit JK, Muijs CT, Burgerhof JG, et al. Survival after definitive (chemo) radiotherapy in esophageal cancer patients:a population-based study in the North-East Netherlands[J]. Ann Surg Oncol,2013,20(6):1985-1992. [15]乔学英,周道安,高献书,等.后程加速超分割放射加顺铂治疗食管癌的临床研究[J].中华放射肿瘤学杂志,2005,14(5):395-397. [16]Hurmuzlu M,Monge OR, Smaaland R, et al. High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer:toxicity and outcome[J]. Dis Esophagus,2010,23(3):244-252.DOI:10.1111/j.1442-2050.2009.00999.x. [17]Sun DR. Ten-year follow-up of esophageal cancer treated by radical radiation therapy:analysis of 869 patients[J]. Int J Radiat Oncol Bilo Phys,1989,16(2):329-334. [18]肖泽芬,章众,张红志,等.用三维治疗计划系统评估食管癌常规放射治疗中肿瘤剂量的分布[J].中华放射肿瘤学杂志,2004,13(4):273-277. [19]蒋杰,王奇峰,肖泽芬,等.132例食管癌三维适形放疗的疗效分析[J].中华放射肿瘤学杂志,2009,18(1):47-51. [20]Zhao KL, Ma JB, Liu G, et al. Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma:is elective nodal irradiation necessary?[J].Int J Radiat Oncol Biol Phys,2010,76(2):446-451.DOI:1.1016/j.ijrobp.2009.02.078.
2015, Vol. 24 
